New Developments in the Pharmacologic Treatment of Obesity

Authors


  • The author discloses that she is currently serving on a women's health advisory board for Watson Pharmaceuticals, for which she receives financial consideration. Watson Pharmaceuticals does not manufacture the drugs discussed in this article or any products in the same categories as the drugs discussed in this article.

Address correspondence to: Heidi_Fantasia@uml.edu.

Abstract

Obesity, defined as a body mass index (BMI, kg/m2) >30, is a significant public health problem. It's estimated that 50 percent of the U.S. population will be classified as obese by the year 2030. Due to associated health complications and rising health care costs related to obesity, new treatment options are being explored. For people who need additional treatment beyond lifestyle modification, new pharmacologic options have been developed that may assist in reducing BMI. Health care providers and patients should consider each person's individual health history and consider both the potential risks and benefits of these therapies.

Ancillary